Compare medicines
Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.
| Attribute | ||
|---|---|---|
| In short | Targeted antibody for HER2-positive breast cancer. | Hormone therapy that has saved hundreds of thousands from breast cancer. |
| Body system | Cancer | Cancer |
| Drug class | Targeted antibodies | Selective oestrogen receptor modulators |
| Supply | Prescription onlyWHO essential medicine | Prescription onlyWHO essential medicine |
| Main uses | HER2-positive breast cancer (early and advanced), HER2-positive stomach cancer | Hormone-receptor-positive breast cancer (pre- and post-menopause), Breast cancer prevention in high risk, Male breast cancer |
| How it works | Locks onto a growth signal on some breast cancer cells and flags them for destruction. | Stops oestrogen fuelling breast cancer cells. |
| Starts working | — | — |
| Half-life | About 28 days | 5–7 days |
| Typical adult dose | IV loading then every 3 weeks for a year (early breast cancer), or 600 mg subcutaneously every 3 weeks. | 20 mg once a day for 5–10 years. |
| Forms | IV infusion, Subcutaneous injection | Tablet, Oral solution |
| Common side effects | Infusion reactions, Diarrhoea, Tiredness | Hot flushes, Vaginal discharge, Irregular periods, Mood changes |
| Serious side effects | Heart muscle weakness, Lung problems (rare) | Blood clots, Womb cancer (post-menopause), Stroke, Cataracts |
| Don't take if | — | Pregnancy; History of blood clots (caution); Taking potent CYP2D6 inhibitors (paroxetine, fluoxetine) — reduces effect; Undiagnosed vaginal bleeding |
| Alcohol | — | Usually no problem in moderation. No specific interaction. |
| Pregnancy | Usually avoidedCan reduce amniotic fluid; contraception for 7 months after. | Usually avoidedCan harm the fetus; avoid pregnancy for 2 months after stopping. |
| Breastfeeding | — | Usually avoidedAvoid. |
| In use since | 1998 | 1973 |
| Brand names | United States: Herceptin, Ogivri, KanjintiUnited Kingdom: Herceptin, Herzuma, OntruzantIndia: CANMAb, Hertraz, Vivitra | United States: SoltamoxUnited Kingdom: Nolvadex-D, SoltamoxIndia: Tamodex, Mamofen |
| Legal status | — | United States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM)India: Schedule H |
| ATC code | L01FD01 | L02BA01 |
Taken together
No interaction between these medicines is recorded in the atlas.
Open in the interaction checker